Intensive Lifestyle Intervention Improves GI Symptoms in T2DM

This article originally appeared here.
Share this content:
Intensive Lifestyle Intervention Improves GI Symptoms in T2DM
Intensive Lifestyle Intervention Improves GI Symptoms in T2DM

FRIDAY, Oct. 23, 2015 (HealthDay News) -- An intensive lifestyle intervention (ILI) can reduce gastrointestinal symptoms among overweight and obese adults with type 2 diabetes, according to research published in the October issue of Clinical Diabetes.

Rebecca H. Neiberg, from the Wake Forest School of Medicine in Winston-Salem, N.C., and colleagues examined whether an ILI would reduce gastrointestinal symptoms over four years of follow-up. Overweight and obese adults with type 2 diabetes were randomized to ILI or diabetes support and education as part of the Action for Health in Diabetes (Look AHEAD) trial.

The researchers found that there was a significant reduction in the prevalence and severity of gastrointestinal symptoms over four years in the ILI group. The largest reductions were seen for bloating, heartburn, and regurgitation. The greatest benefits tended to be seen in the first year of the intervention, which also saw the greatest reductions in weight. The intervention effects were accounted for by inclusion of one-year weight losses in models. After adjustment for metformin and insulin use, the gastrointestinal benefits of the intervention were evident.

"Our findings suggest that weight loss through an intensive lifestyle change intervention may be beneficial to many obese individuals with type 2 diabetes who suffer from most common gastrointestinal symptoms," the authors write.

The Look AHEAD trial was funded by pharmaceutical and weight loss nutrition companies.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Salmonella Outbreak in 26 States Linked to Raw Turkey Products

<i>Salmonella</i> Outbreak in 26 States Linked to Raw ...

40 individuals have been hospitalized to date; no deaths have been reported

FDA Recalls Drugs Containing Active Ingredient Valsartan

FDA Recalls Drugs Containing Active Ingredient Valsartan

All lots of non-expired products that contain valsartan supplied by Zhejiang Huahai being recalled

Atopic Dermatitis Places Heavy Burden on Patients

Atopic Dermatitis Places Heavy Burden on Patients

Overall and mental health, life satisfaction all impacted, especially for moderate, severe disease

is free, fast, and customized just for you!




Already a member?

Sign In Now »